SCHEMBL1928274

SCHEMBL1928274

CC(C)N1C(=O)N(C2CCN(C(=O)OC(C)(C)C)CC2)[C@H]2CCCC[C@@H]21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.45
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
THRB P10828 1/20 0.44
HPGD P15428 1/20 0.44
HCAR1 Q9BXC0 1/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GPR119 Q8TDV5 5/20 0.40
TP53 P04637 1/20 0.40
RECQL P46063 1/20 0.40
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
CTSD P07339 1/20 0.39
CTSE P14091 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1930034 0.84 EPHX1 (0.48) EPHX1MAPTKDM4ETHRBHPGD
SCHEMBL4421699 0.82 OPRM1 (0.40) ALDH1A1
SCHEMBL13380625 0.81 OPRM1 (0.57) EPHX1MAPTKDM4ETHRBHPGD
SCHEMBL13380553 0.81 OPRM1 (0.57) EPHX1MAPTKDM4ETHRBHPGD
SCHEMBL1929465 0.80 CHRM1 (0.51) KDM4ETHRBMAPK1L3MBTL1TP53
SCHEMBL1928616 0.80 OPRM1 (0.45) EPHX1MAPTKDM4ETHRBHPGD
SCHEMBL8224275 0.78 OPRM1 (0.47) KDM4EL3MBTL1
SCHEMBL3409479 0.77 EPHX1 (0.44) EPHX1MAPTKDM4ETHRBHPGD
SCHEMBL1930600 0.77 OPRM1 (0.42) EPHX1MAPTKDM4ETHRBHPGD
SCHEMBL1928269 0.76 EPHX1 (0.48) EPHX1MAPTKDM4ETHRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
WO-2007142583-A1 MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. ASTRAZENECA AB (SE) 2007-12-13 WO disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287695-A1 Novel Compounds OPRM1, OPRL1, OPRK1 EPHX1 1448/4885MAPT 2847/4885KDM4E 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.